Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.9% on Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was down 4.9% during mid-day trading on Friday after an insider sold shares in the company. The company traded as low as $6.52 and last traded at $6.57. Approximately 1,149,152 shares changed hands during trading, a decline of 80% from the average daily volume of 5,710,360 shares. The stock had previously closed at $6.91.

Specifically, CFO Michael Secora sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the sale, the chief financial officer now directly owns 1,499,631 shares in the company, valued at $11,487,173.46. This represents a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total value of $87,455.08. Following the transaction, the director now owns 7,066,113 shares in the company, valued at approximately $53,985,103.32. This trade represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Analyst Ratings Changes

RXRX has been the subject of several research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, November 7th. Jefferies Financial Group lowered their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Finally, Leerink Partners cut their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $9.25.

Recursion Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The stock has a market cap of $1.74 billion, a PE ratio of -4.04 and a beta of 0.81. The stock has a 50 day moving average of $6.66 and a two-hundred day moving average of $7.60.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business’s revenue was up 147.6% on a year-over-year basis. During the same period last year, the business earned ($0.43) earnings per share. Equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Allspring Global Investments Holdings LLC acquired a new position in Recursion Pharmaceuticals during the third quarter valued at $25,000. Farther Finance Advisors LLC grew its stake in Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after acquiring an additional 4,091 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Recursion Pharmaceuticals by 1,588.4% in the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after purchasing an additional 6,036 shares during the period. KBC Group NV lifted its position in shares of Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after purchasing an additional 3,377 shares in the last quarter. Finally, Amalgamated Bank boosted its holdings in shares of Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after purchasing an additional 2,459 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.